Sanofi, a global biopharmaceutical company focused on human health, completed the acquisition of Principia Biopharma, a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, for $3.68bn. “This acquisition advances our ongoing R&D transformation to accelerate development of the most promising medicines that will address significant patient needs. The addition of multiple BTK inhibitors to our pipeline demonstrates our commitment to strategic product acquisitions in our priority therapeutic areas. Full ownership of our brain-penetrant BTK inhibitor ‘168 removes complexities for this priority development program and simplifies future commercialization," Paul Hudson, Sanofi CEO.